PL2114452T3 - Ulepszone kompozycje lecznicze zawierające buprenorfinę i nalmefen - Google Patents

Ulepszone kompozycje lecznicze zawierające buprenorfinę i nalmefen

Info

Publication number
PL2114452T3
PL2114452T3 PL08709413T PL08709413T PL2114452T3 PL 2114452 T3 PL2114452 T3 PL 2114452T3 PL 08709413 T PL08709413 T PL 08709413T PL 08709413 T PL08709413 T PL 08709413T PL 2114452 T3 PL2114452 T3 PL 2114452T3
Authority
PL
Poland
Prior art keywords
nalmefene
buprenorphine
medicinal compositions
improved medicinal
improved
Prior art date
Application number
PL08709413T
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of PL2114452T3 publication Critical patent/PL2114452T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08709413T 2007-03-01 2008-02-15 Ulepszone kompozycje lecznicze zawierające buprenorfinę i nalmefen PL2114452T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene
PCT/GB2008/000522 WO2008104736A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene
EP08709413.2A EP2114452B1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Publications (1)

Publication Number Publication Date
PL2114452T3 true PL2114452T3 (pl) 2014-09-30

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08709413T PL2114452T3 (pl) 2007-03-01 2008-02-15 Ulepszone kompozycje lecznicze zawierające buprenorfinę i nalmefen

Country Status (22)

Country Link
US (1) US8497280B2 (pl)
EP (1) EP2114452B1 (pl)
JP (1) JP5577102B2 (pl)
KR (1) KR101437461B1 (pl)
CN (1) CN101622012B (pl)
AR (1) AR065582A1 (pl)
AU (1) AU2008220572B2 (pl)
BR (1) BRPI0807903A2 (pl)
CA (1) CA2678568C (pl)
CL (1) CL2008000607A1 (pl)
DK (1) DK2114452T3 (pl)
ES (1) ES2476865T3 (pl)
GB (1) GB2447013A (pl)
HK (1) HK1139868A1 (pl)
HR (1) HRP20140591T1 (pl)
MX (1) MX2009009134A (pl)
PE (2) PE20090625A1 (pl)
PL (1) PL2114452T3 (pl)
PT (1) PT2114452E (pl)
TW (1) TWI468163B (pl)
WO (1) WO2008104736A1 (pl)
ZA (1) ZA200905692B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
ME02622B (me) * 2009-05-25 2017-06-20 H Lundbeck As Pripremanje nalmefen hidrohlorida od naltreksona
EA201491875A1 (ru) 2012-04-17 2015-04-30 Пурдью Фарма Л.П. Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
CN112272554A (zh) * 2018-02-22 2021-01-26 艾维奥尔股份有限公司 经粘膜的膜组合物及其制备和使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
WO2008088331A1 (en) * 2007-01-19 2008-07-24 Gloucester Pharmaceuticals Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
US20100152222A1 (en) 2010-06-17
EP2114452B1 (en) 2014-04-09
GB0703933D0 (en) 2007-04-11
PE20120956A1 (es) 2012-08-01
EP2114452A1 (en) 2009-11-11
US8497280B2 (en) 2013-07-30
GB2447013A (en) 2008-09-03
BRPI0807903A2 (pt) 2014-06-17
AU2008220572B2 (en) 2014-03-27
PT2114452E (pt) 2014-07-15
TW200900067A (en) 2009-01-01
ZA200905692B (en) 2010-10-27
KR101437461B1 (ko) 2014-09-05
CA2678568A1 (en) 2008-09-04
JP2010520184A (ja) 2010-06-10
PE20090625A1 (es) 2009-06-04
KR20090115862A (ko) 2009-11-09
ES2476865T3 (es) 2014-07-15
CL2008000607A1 (es) 2008-10-03
MX2009009134A (es) 2009-09-03
AR065582A1 (es) 2009-06-17
CN101622012A (zh) 2010-01-06
CN101622012B (zh) 2012-05-30
DK2114452T3 (da) 2014-06-30
TWI468163B (zh) 2015-01-11
HK1139868A1 (en) 2010-09-30
AU2008220572A1 (en) 2008-09-04
CA2678568C (en) 2015-06-16
WO2008104736A1 (en) 2008-09-04
HRP20140591T1 (hr) 2014-09-12
JP5577102B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
HRP20182124T1 (hr) Farmaceutski sastavi s trenutnim oslobađanjem koji sadrže oksikodon i nalokson
ZA200905689B (en) Improved medicinal compositions comprising buprenorphine and naltrexone
ZA200905691B (en) Improved medicinal compositions comprising buprenorphine and naloxone
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA201203709B (en) Immunogenic compositions and methods
ZA201001300B (en) Antigen-asjuvant compositions and methods
ZA200804305B (en) Pharmaceutical compositions comprising buprenorphine
EP2086318A4 (en) NEUROPROTEKTIVE COMPOSITIONS AND METHOD
ZA201008887B (en) Oral compositions and uses thereof
ZA201007920B (en) Oral compositions and uses thereof
ZA200807614B (en) Buprenorphine derivatives and uses thereof
GB0721291D0 (en) Methods and compositions
HK1139868A1 (en) Improved medicinal compositions comprising buprenorphine and nalmefene
HK1139153A1 (en) Quinolone compound and pharmaceutical composition
GB0719526D0 (en) Compositions and methods
GB0715428D0 (en) Compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0906043D0 (en) Nalmefene compositions and their therapeutic use
GB0906045D0 (en) Nalmefene compositions and their therapeutic use
GB0906044D0 (en) Nalmefene compositions and their therapeutic use
GB0906042D0 (en) Nalmefene compositions and their therapeutic use
GB0906046D0 (en) Nalmefene compositions and their therapeutic use
GB0724549D0 (en) Compositions and methods